Jeena Sikho Lifecare Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹222Cr
- +91.4% YoY
- +16.8% QoQ
- Net profit
- ₹67Cr
- +415.4% YoY
- +13.6% QoQ
- Margin
- 45%
- +19 pp YoY
- −3 pp QoQ
Guidance rank: #11 of 36 in Leisure Services
See the sector's top 10 — free with your mobile number.
Jeena Sikho Lifecare Ltd Q3 FY26 key numbers
- Revenue
- OTC product portfolio expected to expand to 16 products by end of 2026, with monthly sales goals of INR10 crores for initial products and INR500 crores OTC revenue in 2 years.
As stated in Jeena Sikho Lifecare Ltd's Q3 FY26 earnings call transcript · published 1 Jun 2026. Reported figures, not investment advice.
The short version
Target to reach INR1,000 crores profit from sales over the next 3-4 years, representing a 4x to 5x increase from current levels (Page 17). Current profit expected to be approximately INR 225 crores for the year.
From Jeena Sikho Lifecare Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Target to reach INR1,000 crores profit from sales over the next 3-4 years, representing a 4x to 5x increase from current levels (Page 17).
- Focus on increasing operational beds from current ~2,200 to 7,000–10,000 beds within 3-5 years, targeting 70%-80% occupancy (Pages 16-17).
- OTC product portfolio expected to expand to 16 products by end of 2026, with monthly sales goals of INR10 crores for initial products and INR500 crores OTC revenue in 2 years (Pages 4, 17-18).
2 more points from Jeena Sikho Lifecare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jeena Sikho Lifecare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current capex per bed is INR 3 to 4 lakh; setting up 100 beds costs approximately INR 3 to 4 crores.
- Plan to increase total beds to 7,000 to 10,000 over the next 3 to 5 years (currently around 2,800 beds, 2,290 operational).
- Intention to focus on internal growth within Ayurvedic products, services, international business, and diagnostics.
- No plans to expand beyond Ayurveda-related fields; aim to become market leader in Ayurveda in India, Asia, and then globally.
- Exploring high-level acquisitions or tie-ups to accelerate growth, but such discussions are ongoing and subject to valuation negotiations.
- Launching multiple new Ayurvedic products this year (targeting 16 products by December 2026) to drive revenue growth.
2 more points from Jeena Sikho Lifecare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Leisure Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jeena Sikho Lifecare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Jeena Sikho Lifecare Ltd — Quarterly revenue & net profit
Jeena Sikho Lifecare Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 222 | 116 | +91.4% | 190 | +16.8% |
| Operating profit (EBITDA) | 101 | 30 | +236.7% | 92 | +9.8% |
| Operating margin | 45% | 26% | +19 pp | 48% | -3 pp |
| Profit before tax | 89 | 18 | +394.4% | 79 | +12.7% |
| Net profit (PAT) | 67 | 13 | +415.4% | 59 | +13.6% |
| EPS (₹) | 5.37 | 1.06 | +406.6% | 4.73 | +13.5% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹235 Cr, net profit ₹36 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jeena Sikho's management said in earlier quarters
Others in Leisure Services this season
- Sinclairs Hotels (Q3 FY26)
1780.49 lakh, up 23.40% year-on-year. Key investor presentation takeaways from Sinclairs Hotels's Q3 FY26 investor presentation — and how it ranks against secto
- ITC Hotels (Q3 FY26)
Q3 FY26 Revenue from Operations (Standalone): ₹1,052 Cr, up 12% YoY (Page 45) . Key concall takeaways from ITC Hotels Ltd's Q3 FY26 earnings call — and how it…
- EIH Associated Hotels (Q3 FY26)
Q3 FY26 Revenue from Operations: Rs 129.5 crores, down from Rs 133.0 crores in Q3 FY25 (approx. Key concall takeaways from EIH Associated Hotels Ltd's Q3 FY26…
- Easy Trip Planners (Q3 FY26)
Q3 FY26 Revenue from Operations: INR 151.7 Cr (Page 5) . Key concall takeaways from Easy Trip Planners Ltd's Q3 FY26 earnings call — and how it ranks against…
Potential multibaggers · Q2 FY27
Potential multibaggers in Leisure Services
on management's own guidance
- Grand ContinentGood growth2
- Kamat HotelsGood growth1
- Landmark GlobalGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jeena Sikho Lifecare Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jeena Sikho Lifecare Ltd Q3 FY26 results?
Target to reach INR1,000 crores profit from sales over the next 3-4 years, representing a 4x to 5x increase from current levels (Page 17). Current profit expected to be approximately INR 225 crores for the year.
What is Jeena Sikho Lifecare Ltd share price analysis?
Jeena Sikho Lifecare Ltd currently shows a neutral. The stock trades at a P/E of 32.4 with a market cap of ₹7,200 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jeena Sikho Lifecare Ltd planning capital expenditure?
Current capex per bed is INR 3 to 4 lakh; setting up 100 beds costs approximately INR 3 to 4 crores.
Keep Jeena Sikho Lifecare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
